Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
3.90% $4.26
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 383.26 mill |
EPS: | -0.130 |
P/E: | -32.77 |
Earnings Date: | Apr 29, 2024 |
SharesOutstanding: | 89.97 mill |
Avg Daily Volume: | 1.997 mill |
RATING 2024-03-28 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -32.77 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.69x |
Company: PE -32.77 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.74 - 4.76 ( +/- 11.98%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Schobel Alexander Mark | Sell | 50 000 | Common Stock |
2024-03-09 | Barber Daniel | Sell | 37 938 | Common Stock |
2024-03-09 | Boyd Peter E. | Sell | 8 370 | Common Stock |
2024-03-09 | Braender Lori J | Sell | 10 530 | Common Stock |
2024-03-09 | Toth A Ernest Jr | Sell | 11 705 | Common Stock |
INSIDER POWER |
---|
89.93 |
Last 98 transactions |
Buy: 6 570 786 | Sell: 225 172 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.26 (3.90% ) |
Volume | 7.20 mill |
Avg. Vol. | 1.997 mill |
% of Avg. Vol | 360.51 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.67 | N/A | Active |
---|
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.